Skip to main content
MarketStoryBook

Altimmune, Inc. in 1 story

The narratives ALT currently appears in, with its side and exposure in each.

Bull side

1 story
  • GLP-1 Eats Everything

    ALT in “GLP-1 Eats Everything”

    FadingExposure: not rated yet

    Appetite suppression as a macro variable.

    Pemvidutide offers direct exposure to the obesity and metabolic-liver-disease markets, including demand for therapies with favorable body-composition outcomes.

Bear side

0 stories

No bear-side stories for ALT yet.